MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

Strona główna・Stock List・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Closed

1.31 -2.96

Buy Sell

Overview

Share price change

24h

Current

Min

1.3

Max

1.37

Key metrics
By Trading Economics
Income	2.7M -24M
EPS	-0.354
Employees	49
EBITDA	-5.3M -28M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+97.78% upside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	-8.4M 73M
Previous open	4.27
Previous close	1.31

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.43 / 1.6 Support & Resistance

Pliant Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

6 kwi 2026, 23:17 UTC

Earnings

Samsung Forecasts Record First-Quarter Operating Profit

6 kwi 2026, 23:00 UTC

Hot Stocks

Stocks to Watch: Health Insurers, Mawson, Owlet

6 kwi 2026, 22:13 UTC

Major Market Movers

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6 kwi 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6 kwi 2026, 17:09 UTC

Major Market Movers

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6 kwi 2026, 16:56 UTC

Major News Events

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6 kwi 2026, 14:47 UTC

Major Market Movers

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7 kwi 2026, 00:00 UTC

Major News Events

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6 kwi 2026, 23:58 UTC

Market Talk

Major News Events

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6 kwi 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6 kwi 2026, 23:36 UTC

Market Talk

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6 kwi 2026, 23:15 UTC

Market Talk

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6 kwi 2026, 22:52 UTC

Market Talk

Global Equities Roundup: Market Talk

6 kwi 2026, 22:52 UTC

Market Talk

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6 kwi 2026, 22:14 UTC

Market Talk

Correction to Live Cattle Futures Article

6 kwi 2026, 20:56 UTC

Market Talk

Mexican Private Consumption Fell in January -- Market Talk

6 kwi 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

6 kwi 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 kwi 2026, 19:58 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 kwi 2026, 19:58 UTC

Market Talk

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6 kwi 2026, 19:11 UTC

Market Talk

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6 kwi 2026, 19:06 UTC

Market Talk

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6 kwi 2026, 19:03 UTC

Market Talk

Global Energy Roundup: Market Talk

6 kwi 2026, 19:03 UTC

Market Talk

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6 kwi 2026, 18:36 UTC

Acquisitions, Mergers, Takeovers

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 kwi 2026, 17:59 UTC

Market Talk

Major News Events

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6 kwi 2026, 17:13 UTC

Acquisitions, Mergers, Takeovers

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 kwi 2026, 16:33 UTC

Market Talk

Oil Futures Steady as Market Awaits Trump -- Market Talk

6 kwi 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 kwi 2026, 14:59 UTC

Earnings

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Peer Comparison

Price change

Pliant Therapeutics Inc Forecast

Price Target

By TipRanks

97.78% upside

12 Months Forecast

Average 2.67 USD 97.78%

High 3 USD

Low 2 USD

Based on 5 Wall Street analysts offering 12 month price targets forPliant Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Pliant Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.43 / 1.6Support & Resistance

Recent bearish events outweigh bullish events.

There is one bearish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.